AbbVie Submits NDA for Tavapadon: A Breakthrough in Parkinson’s

The biopharmaceutical company, AbbVie, submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for Tavapadon, a new drug targeting the D1 and D5 dopamine receptors that are involved in movement for Parkinson’s patients. The controlled boost will help improve movement, giving Parkinson’s patients smoother motor function and improved coordination.

The ‘TEMPO’ program conducted by AbbVie was divided into four studies: a ‘Fixed Dose,’ a ‘Flexible Dose,’ ‘Parkinson’s with Motor Fluctuations,(patients already on levodopa), and a ‘long-term open-label extension (to study safety and durability).’

The four studies of the program resulted in improved motor symptoms with Tavapadon in early Parkinson’s and increased high-quality ‘on’ time in patients with motor fluctuations. Side effects reported by participants in the trials were mostly mild to moderate, and Tavapadon was generally well received by the participants.

What are Dopamine Receptors?

Dopamine receptors are specialized proteins on brain cells that respond to the chemical messenger dopamine. Dopamine is a neurotransmitter in the brain that helps nerve cells communicate with each other. It plays significant roles in movement, motivation, reward, mood, and hormone regulation.

There are five types of dopamine receptors, which are grouped into two” families “called D1and D2-like receptors. D1- receptors (D1, D5) activate brain pathways that help support movement, attention, and learning. The D2 receptors (D2, D3, D4) are responsible for regulating behavior, decision-making, mood, and motivation.

Medications like Pramipexole and Ropinirole are used to treat Parkinson’s disease, specifically the D2 and D3 receptors, to help compensate for the loss of natural dopamine, while Levadopa boosts dopamine for D1 and D5 receptors. Traditional dopamine agonists overstimulate other receptors (especially D2/D3).

Tavapadon targets the D1/D5 receptors partially, to help restore smoother movement in Parkinson’s disease without triggering the excessive dopamine activity that causes side effects.

Approval

Approval of the drug could happen sometime in late 2026, though the review process for a new drug of this type could take anywhere from six months to two years.

If approved, Tavapadon will offer Parkinson’s patients a once daily oral treatment. You can read the press release about Tavapadon on AbbVie’s website here. You can also read more about the studies at www.clinicaltrials.gov: TEMPO-1: NCT04201093 TEMPO-2: NCT04223193 TEMPO-3: NCT04542499 TEMPO-4: NCT04760769

Unless noted, all media by Chris Denny

Originally published at https://ourworldinwordsandfilm.com on November 22, 2025.